| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IKT Stock Overview
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain.
Inhibikase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$2.54 |
| 52 Week Low | US$0.60 |
| Beta | 0 |
| 1 Month Change | 8.87% |
| 3 Month Change | 38.10% |
| 1 Year Change | -51.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.65% |
Recent News & Updates
Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Inhibikase Therapeutics press release (NASDAQ:IKT): Q2 GAAP EPS of -$0.18. Revenue of $6.55K (-99.5% Y/Y). Cash and cash equivalents were $32.2 million as of June 30, 2022. The Company expects that existing cash and cash equivalents will be sufficient to fund its normal operations and capital expenditure requirements through December 31, 2023. Shares -2.73%.
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Shareholder Returns
| IKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.2% | 1.2% | 1.3% |
| 1Y | -51.6% | -23.0% | -11.7% |
Return vs Industry: IKT underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: IKT underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| IKT volatility | |
|---|---|
| IKT Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IKT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IKT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Milton Werner | https://www.inhibikase.com |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases.
Inhibikase Therapeutics, Inc. Fundamentals Summary
| IKT fundamental statistics | |
|---|---|
| Market Cap | US$23.34m |
| Earnings (TTM) | -US$16.79m |
| Revenue (TTM) | US$1.74m |
13.4x
P/S Ratio-1.4x
P/E RatioIs IKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKT income statement (TTM) | |
|---|---|
| Revenue | US$1.74m |
| Cost of Revenue | US$11.94m |
| Gross Profit | -US$10.20m |
| Other Expenses | US$6.58m |
| Earnings | -US$16.79m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 12, 2022
| Earnings per share (EPS) | -0.67 |
| Gross Margin | -586.66% |
| Net Profit Margin | -965.21% |
| Debt/Equity Ratio | 0.0% |
How did IKT perform over the long term?
See historical performance and comparison